Literature DB >> 2879104

Eligibility for thrombolytic therapy in acute myocardial infarction.

J D Jagger, R G Murray, M K Davies, W A Littler, E J Flint.   

Abstract

In a district general hospital's coronary care unit (CCU) 197 patients with chest pain were admitted over a 6-month period and in 131 an acute myocardial infarction (AMI) was confirmed. 67 (51%) were eligible for thrombolytic therapy, on criteria laid down for a trial of streptokinase. Criteria for thrombolysis were not fulfilled in 41 (31%) and 12 patients (9%) had contraindications. These results suggest that around half of all patients with AMI and about one-third of patients presenting with chest pain and admitted to a CCU would be suitable for thrombolytic therapy. These data do not support the view that such therapy may be applicable to only a small minority of patients with AMI.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2879104     DOI: 10.1016/s0140-6736(87)90715-x

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  5 in total

1.  Impact of a policy of direct admission to a coronary care unit on use of thrombolytic treatment.

Authors:  J M Burns; K J Hogg; A P Rae; W S Hillis; F G Dunn
Journal:  Br Heart J       Date:  1989-04

Review 2.  Coronary thrombolysis.

Authors:  D de Bono
Journal:  Br Heart J       Date:  1987-04

3.  Hospital Protocols and Policies that may Delay Early Identification and Thrombolytic Therapy of Acute Myocardial Infarction Patients.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1996       Impact factor: 2.300

4.  Emergency primary coronary angioplasty in patients with acute myocardial infarction who are unsuitable for intravenous thrombolysis.

Authors:  C J McKenna; M Codd; H A McCann; D D Sugrue
Journal:  Ir J Med Sci       Date:  1995 Oct-Dec       Impact factor: 1.568

5.  Coronary revascularization after thrombolytic therapy for myocardial infarction: what caseloads could Canadian centres face?

Authors:  J S Floras; C D Naylor; P W Armstrong
Journal:  CMAJ       Date:  1989-10-15       Impact factor: 8.262

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.